PMC:7534795 / 35823-39434 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T177","span":{"begin":365,"end":373},"obj":"Body_part"},{"id":"T178","span":{"begin":401,"end":408},"obj":"Body_part"},{"id":"T179","span":{"begin":659,"end":667},"obj":"Body_part"},{"id":"T180","span":{"begin":2868,"end":2873},"obj":"Body_part"},{"id":"T181","span":{"begin":3074,"end":3082},"obj":"Body_part"},{"id":"T182","span":{"begin":3487,"end":3495},"obj":"Body_part"}],"attributes":[{"id":"A177","pred":"fma_id","subj":"T177","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A178","pred":"fma_id","subj":"T178","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A179","pred":"fma_id","subj":"T179","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A180","pred":"fma_id","subj":"T180","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A181","pred":"fma_id","subj":"T181","obj":"http://purl.org/sig/ont/fma/fma62338"},{"id":"A182","pred":"fma_id","subj":"T182","obj":"http://purl.org/sig/ont/fma/fma62338"}],"text":"Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference\n• Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)\n• N = 55 colchicine + standard care\n• N = 50 standard care\n• Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels\n• Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)\n• Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)\n• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study\n• Primary endpoint of 28-day all-cause mortality\n• Secondary endpoint included acute cardiac injury\n• N = 1219 statin use\n• N = 12, 762 no statin • In-hospital statin use\n• Atorvastatin 83.2%,\n• Rosuvastatin 15.6%\n• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)\n• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone\n• Statin therapy not associated with acute cardiac injury\n• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)\n• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study\n• Patients with comorbid hypertension hospitalized with COVID-19\n• Age 18 to 74 years\n• Primary endpoint of 28-day all-cause mortality\n• N = 188 ACEi/ARB therapy\n• N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension\n• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients\n• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)\n• Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study\n• Patients with elevated troponin\n• History of CVD in 24% of patients\n• N = 3069\n• Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins\n• Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels\n• Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T64","span":{"begin":509,"end":514},"obj":"Body_part"},{"id":"T65","span":{"begin":2868,"end":2873},"obj":"Body_part"}],"attributes":[{"id":"A64","pred":"uberon_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A65","pred":"uberon_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference\n• Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)\n• N = 55 colchicine + standard care\n• N = 50 standard care\n• Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels\n• Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)\n• Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)\n• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study\n• Primary endpoint of 28-day all-cause mortality\n• Secondary endpoint included acute cardiac injury\n• N = 1219 statin use\n• N = 12, 762 no statin • In-hospital statin use\n• Atorvastatin 83.2%,\n• Rosuvastatin 15.6%\n• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)\n• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone\n• Statin therapy not associated with acute cardiac injury\n• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)\n• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study\n• Patients with comorbid hypertension hospitalized with COVID-19\n• Age 18 to 74 years\n• Primary endpoint of 28-day all-cause mortality\n• N = 188 ACEi/ARB therapy\n• N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension\n• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients\n• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)\n• Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study\n• Patients with elevated troponin\n• History of CVD in 24% of patients\n• N = 3069\n• Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins\n• Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels\n• Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)"}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T251","span":{"begin":219,"end":224},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T252","span":{"begin":892,"end":893},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T253","span":{"begin":1459,"end":1460},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T254","span":{"begin":2263,"end":2265},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T255","span":{"begin":2868,"end":2873},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T256","span":{"begin":2868,"end":2873},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T257","span":{"begin":2868,"end":2873},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T258","span":{"begin":2868,"end":2873},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T259","span":{"begin":3133,"end":3142},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T260","span":{"begin":3203,"end":3205},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T261","span":{"begin":3434,"end":3435},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference\n• Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)\n• N = 55 colchicine + standard care\n• N = 50 standard care\n• Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels\n• Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)\n• Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)\n• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study\n• Primary endpoint of 28-day all-cause mortality\n• Secondary endpoint included acute cardiac injury\n• N = 1219 statin use\n• N = 12, 762 no statin • In-hospital statin use\n• Atorvastatin 83.2%,\n• Rosuvastatin 15.6%\n• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)\n• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone\n• Statin therapy not associated with acute cardiac injury\n• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)\n• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study\n• Patients with comorbid hypertension hospitalized with COVID-19\n• Age 18 to 74 years\n• Primary endpoint of 28-day all-cause mortality\n• N = 188 ACEi/ARB therapy\n• N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension\n• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients\n• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)\n• Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study\n• Patients with elevated troponin\n• History of CVD in 24% of patients\n• N = 3069\n• Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins\n• Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels\n• Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)"}

LitCovid-PD-CHEBI

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T90","span":{"begin":163,"end":175},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T91","span":{"begin":1126,"end":1138},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T92","span":{"begin":2897,"end":2909},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference\n• Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)\n• N = 55 colchicine + standard care\n• N = 50 standard care\n• Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels\n• Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)\n• Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)\n• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study\n• Primary endpoint of 28-day all-cause mortality\n• Secondary endpoint included acute cardiac injury\n• N = 1219 statin use\n• N = 12, 762 no statin • In-hospital statin use\n• Atorvastatin 83.2%,\n• Rosuvastatin 15.6%\n• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)\n• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone\n• Statin therapy not associated with acute cardiac injury\n• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)\n• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study\n• Patients with comorbid hypertension hospitalized with COVID-19\n• Age 18 to 74 years\n• Primary endpoint of 28-day all-cause mortality\n• N = 188 ACEi/ARB therapy\n• N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension\n• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients\n• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)\n• Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study\n• Patients with elevated troponin\n• History of CVD in 24% of patients\n• N = 3069\n• Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins\n• Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels\n• Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)"}

LitCovid-sentences

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T145","span":{"begin":786,"end":800},"obj":"Phenotype"},{"id":"T146","span":{"begin":805,"end":813},"obj":"Phenotype"},{"id":"T147","span":{"begin":2136,"end":2148},"obj":"Phenotype"},{"id":"T148","span":{"begin":2217,"end":2229},"obj":"Phenotype"},{"id":"T149","span":{"begin":2406,"end":2418},"obj":"Phenotype"},{"id":"T150","span":{"begin":2606,"end":2618},"obj":"Phenotype"}],"attributes":[{"id":"A145","pred":"hp_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A146","pred":"hp_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A147","pred":"hp_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A148","pred":"hp_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A149","pred":"hp_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A150","pred":"hp_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference\n• Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)\n• N = 55 colchicine + standard care\n• N = 50 standard care\n• Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels\n• Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)\n• Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)\n• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study\n• Primary endpoint of 28-day all-cause mortality\n• Secondary endpoint included acute cardiac injury\n• N = 1219 statin use\n• N = 12, 762 no statin • In-hospital statin use\n• Atorvastatin 83.2%,\n• Rosuvastatin 15.6%\n• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)\n• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone\n• Statin therapy not associated with acute cardiac injury\n• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)\n• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study\n• Patients with comorbid hypertension hospitalized with COVID-19\n• Age 18 to 74 years\n• Primary endpoint of 28-day all-cause mortality\n• N = 188 ACEi/ARB therapy\n• N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension\n• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients\n• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)\n• Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study\n• Patients with elevated troponin\n• History of CVD in 24% of patients\n• N = 3069\n• Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins\n• Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels\n• Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)"}

2_test

{"project":"2_test","denotations":[{"id":"33031856-32302265-84038880","span":{"begin":2936,"end":2940},"obj":"32302265"},{"id":"33031856-32517963-84038881","span":{"begin":3606,"end":3610},"obj":"32517963"}],"text":"Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference\n• Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)\n• N = 55 colchicine + standard care\n• N = 50 standard care\n• Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels\n• Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)\n• Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)\n• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study\n• Primary endpoint of 28-day all-cause mortality\n• Secondary endpoint included acute cardiac injury\n• N = 1219 statin use\n• N = 12, 762 no statin • In-hospital statin use\n• Atorvastatin 83.2%,\n• Rosuvastatin 15.6%\n• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)\n• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone\n• Statin therapy not associated with acute cardiac injury\n• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)\n• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study\n• Patients with comorbid hypertension hospitalized with COVID-19\n• Age 18 to 74 years\n• Primary endpoint of 28-day all-cause mortality\n• N = 188 ACEi/ARB therapy\n• N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension\n• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients\n• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)\n• Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study\n• Patients with elevated troponin\n• History of CVD in 24% of patients\n• N = 3069\n• Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins\n• Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels\n• Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)"}

LitCovid-PubTator

PMC:7534795 / 35823-39434 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7534795 / 35823-39434 JSON TXT